ImmunityBio
IBRX
6.02
-0.55
-8.37%
ImmunityBio
US · IBRX
#1397 by market cap
Listed 1970
6.02
-0.55
-8.37%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:59
Recent news
-
Rating change
H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $10Market Newswire · 2026/2/19
-
Rating change
Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $12Market Newswire · 2026/3/4
-
A Quick Look at Today's Ratings for ImmunityBio(IBRX.US), With a Forecast Between $12 to $16Market Newswire · 2026/10/15
-
Earnings Flash (IBRX) ImmunityBio Posts Q3 Net Loss $0.18 a Share, Vs. FactSet Est of $0.07 LossMT Newswires · 2026/11/9
-
BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $12Market Newswire · 2026/11/10
-
Rating change
BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $13Market Newswire · 2026/3/12
-
Rating change
Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $5Market Newswire · 2025/12/15
-
Rating change
BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $9Market Newswire · 2026/1/23
-
Rating change
BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $9Market Newswire · 2026/2/3
-
Rating change
H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $10Market Newswire · 2026/1/26
-
Rating change
BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Cuts Target Price to $12Market Newswire · 2026/5/8
-
Rating change
Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $12Market Newswire · 2026/9/8
-
Rating change
BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $13Market Newswire · 2026/3/25
-
Rating change
ImmunityBio (IBRX) Receives a Buy From H.C. WainwrightTipRanks · 2026/5/8
-
H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $15Market Newswire · 2026/11/10
-
Rating change
H.C. Wainwright Sticks to Its Buy Rating for ImmunityBio (IBRX)TipRanks · 2026/4/30
-
Rating change
Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $7Market Newswire · 2026/1/20
-
Divergence in Insider Trading Among U.S. Biotech Stocks: ImmunityBio (IBRX.US) Sees Largest Cash-Out, While Sellas (SLS.US) Directors Buy In Before 5-Fold SurgeZhitong Finance · 2026/11/12
-
Rating change
H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $15Market Newswire · 2026/2/24
-
Rating change
H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $8Market Newswire · 2026/1/20
-
Form 144 | ImmunityBio(IBRX.US) Officer Proposes to Sell 7.66 Million in Common StocksMarket Newswire · 2026/10/5
-
H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $15Market Newswire · 2026/10/15
-
Rating change
Jefferies Initiates ImmunityBio(IBRX.US) With Buy Rating, Announces Target Price $9Market Newswire · 2025/12/13
-
BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $12Market Newswire · 2026/10/30
-
BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $12Market Newswire · 2026/8/5
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:59:40 · For reference only, not investment advice and not tailored to your situation.
ImmunityBio discussion 0 comments